MEGAN LUMSDEN: Open Payments
NPI 1215463336 · FLINT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$379 in 22 payments from 8 companies in 2025. Trend: 2023 $975 · 2024 $578 · 2025 $379
Food & beverage: $379
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 5 | $85 |
| ABBVIE INC. | 4 | $69 |
| GlaxoSmithKline, LLC. | 4 | $61 |
| Novo Nordisk Inc | 3 | $57 |
| Lilly USA, LLC | 2 | $40 |
| Amgen Inc. | 2 | $33 |
| AstraZeneca Pharmaceuticals LP | 1 | $19 |
| PFIZER INC. | 1 | $15 |
Products named: Veozah, Ozempic, UBRELVY, TRELEGY ELLIPTA, JARDIANCE, OTEZLA, AIRSUPRA, AREXVY.
Industry payments across MI — which companies pay providers there.
